Table A1.
Reasons for Patients Inclusion and Exclusion From This Analysis
| Status | No. of Patients |
|---|---|
| No. of patients entered | 2,952 |
| Ineligible as of October 29, 2005 | 67 |
| Did not consent to future use of tissue | 341 |
| Unknown ER/PR status | 10 |
| Early lost to follow-up | 11 |
| No blocks submitted | 880 |
| No tumor in block | 64 |
| Total potentially available for case-control sample as of May 23, 2006 | 1,579 |
| Recurrences | 191 |
| Nonrecurrences | 1,388 |
| Selected for case-control sample, total, as of May 23, 2006 | 832 |
| Recurrences | 191 |
| Nonrecurrences | 641 |
| Exclusions based on analyzability of the samples at GHI | |
| Insufficient tumor | |
| Recurrences | 3 |
| Nonrecurrences | 15 |
| Pathology ineligible on GHI review | |
| Recurrences | 3 |
| Nonrecurrences | 10 |
| Insufficient RNA | |
| Recurrences | 5 |
| Nonrecurrences | 12 |
| QPCR sample quality | |
| Recurrences | 1 |
| Nonrecurrences | 6 |
| Average reference gene count > 35 | |
| Recurrences | 1 |
| Nonrecurrences | 0 |
| Total exclusions | |
| Recurrences | 13 |
| Nonrecurrences | 43 |
| Analyzable for case-control sample | 776 |
| Analyzable as of May 23, 2006 | |
| Recurrences | 178 |
| Nonrecurrences | 598 |
| HR-positive cases included in this analysis | |
| Case | 99 |
| Control | 366 |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; GHI, Genomic Health, Inc; QPCR, quantitative polymerase chain reaction; HR, hormone receptor.